Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed advanced, non-squamous, non-small cell lung cancer. * Molecular confirmation of an ALK rearrangement. * Age ≥ 18 years old. * Life expectancy \> 12 weeks. * Performance status 0-2. * Adequate hematologic function: * Adequate renal function: * An estimated Glomerular Filtration Rate (eGFR) of at least 45 mL/min/1.73 m2 * International normalized ration (INR)≤ 1.5 * Partial thromboplastin time (PTT) ≤1.5 x upper limit of normal (ULN) * For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment. * Able and willing to provide written informed consent * Phase II Only: * Presence of at least one measurable central nervous system (CNS) target lesion (At least 5 mm in size) * Lesions must be untreated or progressive according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after previous local therapy. * Participants who are receiving corticosteroids must be on a stable or decreasing dose * At least one measurable extra-CNS lesion based upon RECIST version 1.1. Exclusion Criteria: * Squamous cell histology or mixed, predominantly squamous adenosquamous carcinoma * Previous history of haemoptysis * Tumour infiltrating into large vessels or infiltrating into the proximal tracheobronchial network * Unstable, symptomatic brain metastases. * History of hemorrhagic CNS metastases * History of intracranial hemorrhage (ei…